Clinical Trials Browser

Phase 1 × INDUSTRY × Lymphoma, B-Cell, Marginal Zone × Clear all

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06544265 2026-04-14

SynKIR-310 for Relapsed/Refractory B-NHL

Phase 1 Recruiting

36 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Dendritic Cell Sarcoma, Interdigitating

NCT04903197 2026-04-01

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase 1 Terminated

18 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Clinical Trials

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

SynKIR-310 for Relapsed/Refractory B-NHL

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Study of SGR-1505 in Mature B-Cell Neoplasms

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

ELiPSE-1

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

GLEAN-1

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma